N/A
N=241,981
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Type 2 Diabetes Mellitus · Cardiovascular Diseases
Bottom Line
View on ClinicalTrials.gov: NCT05073692 ↗Enrolled (actual)
241,981
Serious AEs
—
Results posted
Nov 2025
Primary outcome: Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- SU (Drug); DPP4 (Drug); SGLT2i (Drug); GLP-1RA (Drug); SGLT2i or GLP-1RA (Drug); Linagliptin (DPP4) (Drug); Exenatide (GLP-1RA) (Drug); Liraglutide (GLP-1RA) (Drug); Empagliflozin (SGLT2i) (Drug); Glimepiride (SU) (Drug); Glipizide (SU) (Drug); Glimepiride (SU) or Glipizide (SU) (Drug); SU or DPP4 (excluding saxagliptin and alogliptin) (Drug); Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Kaiser Permanente
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of 3-point Major Adverse Cardiovascular Events (MACE) |
11,348; 393; 424; 296 | — |
Summary
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Eligibility Criteria
- Dispensing of either of the set of drugs being compared
- No prior dispensing of nor contraindication for any of the drugs compared
- Evidence of Type 2 Diabetes Mellitus diagnosis
- Age 18 or older
- Not currently pregnant
- No evidence of dementia or short-term life expectancy from prior cancer diagnoses
- History of ≥2 years of continuous health plan membership
- ≥1 A1c test in the past 18 months
Data sourced from ClinicalTrials.gov (NCT05073692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.